LawGrids logoLAWGRIDS.ORG

Rule 32, Drugs (Prices Control) Order, 2013: Non–application of the provisions of this order in certain cases

Drugs (Prices Control) Order, 2013 - Rule 32

Text of rule 32

Non–application of the provisions of this order in certain cases

32. Non–application of the provisions of this order in certain cases.- The provisions of this order shall not apply to, - (i) a manufacturer producing a new drug patented under the Indian Patent Act, 1970 (39 of 1970) (product patent) and not produced elsewhere, if developed through indigenous Research and Development, for a period of five years from the date of commencement of its commercial production in the country. (ii) a manufacturer producing a new drug in the country by a new process developed through indigenous Research and Development and patented under the Indian Patent Act, 1970 (39 of 1970) (process patent) for a period of five years from the date of the commencement of its commercial production in the country. (iii) a manufacturer producing a new drug involving a new delivery system developed through indigenous Research and Development for a period of five years from the date of its market approval in India: Provided that the provision of this paragraph shall apply only when a document showing approval of such new drugs from Drugs Controller General (India) is produced before the Government. Explanation.- Notwithstanding anything contained in this Order, for the purpose of this paragraph “new drug” shall have the same so seized, in a court of law and for their safe custody pending such production; (c) seize any document, such as, cash memo or credit memo books, books of account and records of purchase and sale of the drugs in respect of which he suspects that any provision of this Order has been, is being, or is about to be contravened. (2) The provisions of Code of Criminal Procedure, 1973 (2 of 1974), relating to search and seizure shall, so far as may be, apply to searches and seizures under this Order. 31. Power to review.-— Any person aggrieved by any notification issued or order made under paragraphs 4, 5 and 6 of this Order, may apply to the Government for a review of the notification or order within a period of thirty days of the date of publication of the notification in the Official Gazette or the receipt of the order by him, as the case may be, and the Government may make such order on the application as it may deem proper: Provided that pending a decision by the Government on the application submitted under the above paragraph, no manufacturer shall sell a scheduled formulation or a new drug, as the case may be, at a price exceeding the ceiling price or retail price, as the case may be, fixed by the Government of which a review has been applied for. 32. Non-application of the provisions of this order in certain cases.- The provisions of this order shall not apply to, - (i) a manufacturer producing a new drug patented under the Indian Patent Act, 1970 (39 of 1970) (product patent) and not produced elsewhere, if developed through indigenous Research and Development, for a period of five years from the date of commencement of its commercial production in the country. (ii) a manufacturer producing a new drug in the country by a new process developed through indigenous Research and Development and patented under the Indian Patent Act, 1970 (39 of 1970) (process patent) for a period of five years from the date of the commencement of its commercial production in the country. (iii) a manufacturer producing a new drug involving a new delivery system developed through indigenous Research and Development for a period of five years from the date of its market approval in India: Provided that the provision of this paragraph shall apply only when a document showing approval of such new drugs from Drugs Controller General (India) is produced before the Government. Explanation.- Notwithstanding anything contained in this Order, for the purpose of this paragraph “new drug” shall have the same meaning as is assigned to under rule 122E of the Drugs and Cosmetics Rules, 1945; meaning as is assigned to under rule 122E of the Drugs and Cosmetics Rules, 1945; [SCHEDULE-I National List of Essential Medicines 2015 [See paragraphs-2(t), 2(zb)] (Symbols P, S and T appearing in this Schedule denote essentiality at Primary, Secondary and Tertiary levels respectively) Section 1-Anesthetic agents 1.1-General Anesthetics and oxygen Medicine Level of Healthcare Dosage form and strength 1.1.1 Halothane S,T Inhalation 1.1.2 Isoflurane S,T Inhalation 1.1.3 Ketamine P,S,T Injection 10 mg/ml Injection 50 mg/ml 1.1.4 Nitrous oxide P,S,T Inhalation 1.1.5 Oxygen P,S,T Inhalation (Medicinal gas) 1.1.6 Propofol P,S,T Injection 10 mg/ml 1.1.7 Sevoflurane T Inhalation 1.1.8 Thiopentone P,S,T Powder for Injection 0.5 g Powder for Injection 1 g 1.2-Local anesthetics Medicine Level of Healthcare Dosage form and strength Injection 0.25% Injection 0.5% 1.2.1 Bupivacaine S,T Injection 0.5% with 7.5% glucose Topical forms 2-5% Injection 1% 1.2.2 Lignocaine P,S,T Injection 2% Injection 5% with 7.5% Glucose 1.2.3 Lignocaine (A) + Adrenaline (B) P,S,T Injection 1% (A) + 1 :200000 (5 mcg/ml) (B) Injection 2% (A) + 1 :200000 (5 1.2.4 Prilocaine (A) + Lignocaine (B) T Cream 2.5% (A) + 2.5% (B) 1.3-Preoperative medication and sedation for short term procedures Medicine Level of Healthcare Dosage form and strength 1.3.1 Atropine P,S,T Injection 0.6 mg/ml 1.3.2 Glycopyrrolate S,T Injection 0.2 mg/ml [SCHEDULE-I National List of Essential Medicines 2015 [See paragraphs-2(t), 2(zb)] (Symbols P, S and T appearing in this Schedule denote essentiality at Primary, Secondary and Tertiary levels respectively) Section 1-Anesthetic agents 1.1-General Anesthetics and oxygen Lignocaine (B) Medicine Level of Dosage form and strength Healthcare 1.1.1 Halothane S,T Inhalation 1.1.2 Isoflurane S,T Inhalation 1.1.3 Ketamine P,S,T Injection 10 mg/ml Injection 50 mg/ml 1.1.4 Nitrous oxide P,S,T Inhalation 1.1.5 Oxygen P,S,T Inhalation (Medicinal gas) 1.1.6 Propofol P,S,T Injection 10 mg/ml 1.1.7 Sevoflurane T Inhalation Powder for Injection 0.5 g P for Injection 1 1.1.8 Thiopentone P,S,T owder for Injection I g 1.2-Local anesthetics Medicine Level of Dosage form and strength Healthcare Injection 0.25% Injection 0.5% 1.2.1 Bupivacaine S,T Injection 0.5% with 7.5% glucose Topical forms 2-5% Injection 1% 1.2.2 Lignocaine P,S,T Injection 2% Injection 5% with 7.5% Glucose 1.2.3 Lignocaine (A) + P,S,T Injection 1% (A) + 1 :200000 (5 Adrenaline (B) mcg/ml) (B) Injection 2% (A) + 1 :200000 (5 1.2.4 Prilocaine (A) + T Cream 2.5% (A) + 2.5% (B) 1.3-Preoperative medication and sedation for short term procedures Medicine Level of Dosage form and strength Healthcare 1.3.1 Atropine P,S,T Injection 0.6 mg/ml 1.3.2 Glycopyrrolate S,T Injection 0.2 mg/ml 1.3.3 Midazolam P,S,T Tablet 7.5 mg Tablet 15 mg Oral liquid 2 mg/ml Injection 1 mg/ml Injection 5 mg/ml 1.3.4 Morphine P,S,T Injection 10 mg/ml Injection 15 mg/ml Section 2- Analgesics, antipyretics, non steroidal anti inflammatory medicines, medicines used to treat gout and disease modifying agents used in rheumatoid disorders 2.1- Non-opioid analgesics, antipyretics and no steroidal anti -inflammatory medicines Medicine Level of Healthcare Dosage form and strength 2.1.1 Acetylsalicylicacid P,S,T Tablet 300 mg to 500 mg Effervescent/ Dispersible/ Enteric coated Tablet 300 mg to 500 mg 2.1.2 Diclofenac P,S,T Tablet 50 mg Injection 25 mg/ml 2.1.3 Ibuprofen P,S,T Tablet 200 mg Tablet 400 mg Oral liquid 100 mg/5 ml 2.1.4 Mefenamic acid P,S,T Capsule 250 mg Capsule 500 mg Oral liquid 100 mg/5 ml 2.1.5 Paracetamol P,S,T Tablet 500 mg Tablet 650 mg All licenced oral liquid dosage forms and strengths Injection 150 mg/ml Suppository 80 mg Suppository 170 mg 2.2-Opioid analgesics Medicine Level of Healthcare Dosage form and strength 2.2.1 Fentanyl S,T Injection 50 mcg/ml 2.2.2 Morphine P,S,T Tablet 10 mg Injection 10 mg/ml Injection 15 mg/ml 2.2.3 Tramadol S,T Capsule 50 mg Capsule 100 mg Injection 50 mg/ml 2.3-Medicines used to treat gout Medicine Level of Healthcare Dosage form and strength 2.3.1 Allopurinol P,S,T Tablet 100 mg Tablet 300 mg 2.3.2 Colchicine P,S,T Tablet 0.5 mg 2.4-Disease modifying agents used in rheumatoid disorders Medicine Level of Healthcare Dosage form and strength 2.4.1 Azathioprine S, T Tablet 50 mg 2.4.2 Hydroxychloroquine S,T Tablet 200 mg Tablet 400 mg 1.3.3 Midazolam P.S,T Tablet 7.5 mg Tablet 15 mg Oral liquid 2 mg/ml Injection 1 mg/ml Injection 5 mg/ml 1.3.4 Morphine P,S,T Injection 10 mg/ml Injection 15 mg/ml Section 2- Analgesics, antipyretics, non steroidal anti inflammatory medicines, medicines used to treat gout and| disease modifying agents used in rheumatoid disorders 2.1- Non-opioid analgesics, antipyretics and no steroidal anti -inflammatory medicines Medicine Level of Dosage form and strength Healthcare 2.1.1 Acetylsalicylicacid P,S,T Tablet 300 mg to 500 mg Effervescent/ Dispersible/ Enteric coated Tablet 300 mg to 500 mg 2.1.2 Diclofenac P,S,T Tablet 50 mg Injection 25 mg/ml 2.1.3 Ibuprofen P,S,T Tablet 200 mg Tablet 400 mg Oral liquid 100 mg/5 ml 2.1.4 Mefenamic acid P,S,T Capsule 250 mg Capsule 500 mg Oral liquid 100 mg/5 ml 2.1.5 Paracetamol P,S,T Tablet 500 mg Tablet 650 mg All licenced oral liquid dosage forms and strengths Injection 150 mg/ml Suppository 80 mg Suppository 170 mg 2.2-Opioid analgesics Medicine Level of Dosage form and strength Healthcare 021 Fentanyl S,T Injection 50 mcg/ml 2.2.2 Morphine P,S,T Tablet 10 mg Injection 10 mg/ml Injection 15 mg/ml 2.2.3 Tramadol S,T Capsule 50 mg Capsule 100 mg Injection 50 mg/ml 2.3-Medicines used to treat gout Medicine Level of Dosage form and strength Healthcare Allopurinol P,S,T Tablet 100 mg 23.1 Tablet 300 mg 2.3.2 Colchicine P,S,T Tablet 0.5 mg 2.4-Disease modifying agents used in rheumatoid disorders Medicine Level of Dosage form and strength Healthcare 2.4.1 Azathioprine S, T Tablet 50 mg 2.4.2 Hydroxychloroquine S,T Tablet 200 mg Tablet 400 mg 2.4.3 Leflunomide S,T Tablet 10 mg Tablet 20 mg 2.4.4 Methotrexate S,T Tablet 5 mg Tablet 7.5 mg Tablet 10 mg Injection 25 mg/ ml 2.4.5 Sulfasalazine S, T Tablet 500 mg Section 3-Antiallergics and medicines used in anaphylaxis Medicine Level of Healthcare Dosage form and strength 3.1 Adrenaline P,S,T Injection 1 mg/ml 3.2 Cetirizine P,S,T Tablet 10 mg Oral liquid 5 mg/5ml 3.3 Chlorpheniramine P,S,T Tablet 4 mg Oral liquid 2 mg/5 ml 3.4 Dexamethasone P,S,T Tablet 0.5 mg 3.5 Hydrocortisone P,S,T Powder for Injection 100 mg 3.6 Pheniramine P,S,T Injection 22.75 mg/ml 3.7 Prednisolone P,S,T Tablet 5 mg Tablet 10 mg Tablet 20 mg Oral liquid 5 mg/5 ml Oral liquid 15 mg/5 ml Section 4-Antidotes and other substances used in poisoning 4.1- Nonspecific Medicine Level of Healthcare Dosage form and strength 4.1.1 Activated charcoal P,S,T Powder (as licensed) 4.2-Specific Medicine Level of Healthcare Dosage form and strength 4.2.1 Atropine P,S,T Injection 1 mg/ml 4.2.2 Calcium gluconate P,S,T Injection 100 mg/ml 4.2.3 Desferrioxamine S,T Powder for Injection 500 mg 4.2.4 Dimercaprol S,T Injection 50 mg/ml 4.2.5 Methylthioninium chloride (Methylene blue) S,T Injection 10 mg/ml 4.2.6 N-acetylcysteine P,S,T Sachet 200 mg Injection 200 mg/ml 4.2.7 Naloxone P,S,T m Injection 0.4 mg/ml 4.2.8 Neostigmine P,S,T Injection 0.5 mg/ml 2.4.3 Leflunomide S,T Tablet 10 mg Tablet 20 mg 2.4.4 Methotrexate S,T Tablet 5 mg Tablet 7.5 mg Tablet 10 mg Injection 25 mg/ ml 2.4.5 Sulfasalazine S,T Tablet 500 mg Section 3-Antiallergics and medicines used in anaphylaxis Medicine Level of Dosage form and strength Healthcare Adrenaline P,S,T Injection 1 mg/ml 3.1 3.2 Cetirizine P,S,T Tablet 10 mg Oral liquid 5 mg/Sml 3.3 Chlorpheniramine P,S,T Tablet 4 mg Oral liquid 2 mg/5 ml 3.4 Dexamethasone P,S,T Tablet 0.5 mg 3.5 Hydrocortisone P,S,T Powder for Injection 100 mg 3.6 Pheniramine P,S,T Injection 22.75 mg/ml 3.7 Prednisolone P,S,T Tablet 5 mg Tablet 10 mg Tablet 20 mg Oral liquid 5 mg/5 ml Oral liquid 15 mg/5 ml Section 4-Antidotes and other substances used in poisoning 4.1- Nonspecific Medicine Level of Dosage form and strength Healthcare 4.1.1 Activated charcoal P,S,T Powder (as licensed) 4.2-Specific Medicine Level of Dosage form and strength Healthcare 4.2.1 Atropine P.S,T Injection 1 mg/ml 4.2.2 Calcium gluconate P.S,T Injection 100 mg/ml 4.2.3 Desferrioxamine S,T Powder for Injection 500 mg 4.2.4 Dimercaprol S,T Injection 50 mg/ml 4.2.5 Methylthioninium S,T Injection 10 mg/ml chloride (Methylene blue) 4.2.6 N-acetylcysteine P,S,T Sachet 200 mg Injection 200 mg/ml 4.2.7 Naloxone P,S,T m Injection 0.4 mg/ml 4.2.8 Neostigmine P,S,T Injection 0.5 mg/ml 4.2.9 Penicillamine S,T Capsule 250 mg 4.2.10 Pralidoxime chloride (2- PAM) P,S,T Injection 25 mg/ml 4.2.11 Snake venom antiserum a) Soluble/ liquid polyvalent P,S,T a) Injection b) Powder for Injection 4.2.12 Sodium nitrite S,T Injection 30 mg/ml 4.2.13 Sodium S,T Injection 100 mg/ml Section 5-Anticonvulsants/Antiepileptics Medicine Level of Healthcare Dosage form and strength 5.1 Carbamazepine P,S,T Tablet 100 mg Tablet 200 mg CR Tablet 200 mg Tablet 400 mg CR Tablet 400 mg Oral liquid 100 mg/5 ml Oral liquid 200 mg/5 ml 5.2 Clobazam S,T Tablet 5 mg Tablet 10 mg 5.3 Diazepam P,S,T Oral liquid 2 mg/5 ml Injection 5 mg/ml Suppository 5 mg 5.4 Levetiracetam S,T Tablet 250 mg Tablet 500 mg Tablet 750 mg ER Tablet 750 mg Oral liquid 100 mg/ml Injection 100 mg/ml 5.5 Lorazepam P,S,T Tablet 1 mg Tablet 2 mg Injection 2 mg/ml 5.6 Magnesium sulphate S,T Injection 500 mg/ml 5.7 Phenobarbitone P,S,T Tablet 30 mgTablet 60 mgOral liquid 20 mg/5 ml S,T Injection 200 mg/ml 5.8 Phenytoin P,S,T Tablet 50 mg Tablet 100 mg Tablet 300 mg ER Tablet 300 mg Oral liquid 30 mg/5 ml Oral liquid 125 mg/5 ml Injection 25 mg/ml Injection 50 mg/ml 5.9 Sodium valproate P,S,T Tablet 200 mg Tablet 300 mg CR Tablet 300 mg Tablet 500 mg CR Tablet 500 mg Oral liquid 200 mg/5ml T Injection 100 mg/ml Section 6-Anti infective medicines 6.1-Anthelminthics 6.1.1-Intestinal anthelminthics 4.2.9 Penicillamine S,T Capsule 250 mg 4.2.10 Pralidoxime chloride (2- PAM) P,S,T Injection 25 mg/ml 4.2.11 Snake venom antiserum a) Soluble/ liquid polyvalent P,S,T a) Injection b) Powder for Injection 4.2.12 Sodium nitrite S,T Injection 30 mg/ml 4.2.13 Sodium S,T Injection 100 mg/ml Section 5-Anticonvulsants/Antiepilepti CS Medicine Level of Healthcare Dosage form and strength 5.1 Carbamazepine P,S,T Tablet 100 mg Tablet 200 mg CR Tablet 200 mg Tablet 400 mg CR Tablet 400 mg Oral liquid 100 mg/5 ml Oral liquid 200 mg/5 ml 5.2 Clobazam S,T Tablet 5 mg Tablet 10 mg 5.

Previous and next

All provisions of Drugs (Prices Control) Order, 2013

Questions people ask

Is rule 32 of Drugs (Prices Control) Order, 2013 still in force?

No repeal of Drugs (Prices Control) Order, 2013 is recorded.